Clinicopathological Profile of Low-Grade B Cell Non-Hodgkin Lymphoma in Tertiary Health Care in West Java Indonesia

Background: Low-grade B cell Non-Hodgkin lymphomas (NHL) are a group of lymphomas that are predominantly indolent and make up approximately 50% of all malignant lymphomas. Initial therapy for low-grade B cell LNH has an overall response rate of between 85-94% and a refractory rate of 6-10%. Few reports have been published regarding the clinicopathological characteristics of non-Hodgkin lymphoma cases, especially low-grade B cell types. This research aims to determine the clinicopathological profile of low-grade B cell type non-Hodgkin lymphoma cases. Method: This research is a descriptive study using cross-sectional methods. The sample consisted of 40 low-grade B cell type NHL cases from January 2015 to June 2020 at Hasan Sadikin Hospital, Bandung. Clinicopathological data, including age, sex, location of the tumor (nodal or extranodal), stage, B symptoms, and response to therapy, were taken from the patients’ medical records. Data were categorized into 2 groups based on response to initial therapy. Results and Discussion: Of the 40 cases diagnosed with low-grade B cell type NHL, 55% responded to initial therapy. From the non-response group, 61.1% were stage II and 72.2% exhibited B symptoms. There were no significant differences in age, sex, tumor location (nodal or extranodal), stage, or B symptoms in the response and non-response groups. Conclusion: In this study, 45% of patients with low-grade B cell type NHL did not respond to initial therapy. There was no statistically significant difference in the clinicopathological profiles of the response and non-response groups to initial therapy in cases of low-grade B cell type NHL. Keywords: Non-Hodgkin Lymphoma, low-grade B cell lymphoma, therapy response, clinicopathological

[1]  J. Zaucha,et al.  First‐line R‐CVP versus R‐CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4 , 2019, British journal of haematology.

[2]  D. Bron,et al.  Marginal zone lymphomas: second most common lymphomas in older patients. , 2019, Current opinion in oncology.

[3]  M. Albayrak,et al.  Prognostic Factors in Patients with Low-Grade Nonhodgkin Lymphoma , 2019, Indian Journal of Hematology and Blood Transfusion.

[4]  P. Jain,et al.  Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management , 2019, American journal of hematology.

[5]  E. Steliarova-Foucher,et al.  Global patterns and trends in the incidence of non-Hodgkin lymphoma , 2019, Cancer Causes & Control.

[6]  S. Malek,et al.  Chronic Lymphocytic Leukemia , 2019, Methods in Molecular Biology.

[7]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[8]  C. Suh,et al.  Clinical features and survival outcomes of patients with lymphoplasmacytic lymphoma, including non-IgM type, in Korea: a single-center experience , 2018, Blood research.

[9]  A. Freedman Follicular lymphoma: 2018 update on diagnosis and management , 2018, American journal of hematology.

[10]  Pio Zeppa,et al.  Non-Hodgkin Lymphoma. , 2020, Monographs in clinical cytology.

[11]  L. Quintanilla‐Martinez The 2016 updated WHO classification of lymphoid neoplasias , 2017, Hematological oncology.

[12]  B. Nathwani,et al.  Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project , 2016, Haematologica.

[13]  J. Byrd,et al.  Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[14]  P. Kao,et al.  Update on Diagnosis and Management , 2015 .

[15]  A. Lupu,et al.  Indolent lymphoma: diagnosis and prognosis in medical practice. , 2013, Maedica.

[16]  S. Clarke,et al.  Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients – analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO , 2009, BMC Cancer.